CLA (Conjugated Linoleic Acid) for Obesity

CLA (conjugated linoleic acid) does not treat obesity. In a meta-analysis of 13 placebo-controlled trials in overweight and obese adults, CLA lowered body weight by 0.52 kg and fat mass by 0.61 kg more than placebo, and waist size did not change; the authors concluded that its efficacy "was not clinically considerable" [1]. Reviews of longer trials and of weight-loss supplements reach the same verdict: the effects are real but small, below the 2.5 kg one review set as the threshold for clinical significance [2][3].

That matters more for obesity than for general weight control. NIDDK suggests losing 5% of body weight over 6 months as a good first goal [4], which is about 5 kg for a 100 kg adult, roughly ten times what CLA adds. Trials in people with obesity also raise specific concerns: a 1-year trial found CLA did not slow weight regain after dieting [12], and the purified trans-10,cis-12 isomer made insulin resistance worse in abdominally obese men [8]. For the general picture across all weights, see CLA for weight loss.

CLA is a group of isomers of linoleic acid, an omega-6 fat. The products tested in trials often contained its cis-9,trans-11 and trans-10,cis-12 isomers in a 50:50 ratio [10][13]. The proposed actions are on fat tissue itself: more breakdown of stored fat (lipolysis), less fat building (lipogenesis) and the death of fat cells (apoptosis) [6].

CLA reduces fat mass in animals, but results in humans have been inconsistent [7]. An older 2007 pooled estimate put the effect at about 0.09 kg of fat a week more than placebo at 3.2 g a day, rising for about 6 months and then slowing [7]; later, larger reviews put the total effect much lower, at about 0.4-0.6 kg [1][5].

The isomer thought to drive fat loss is also the one that harmed metabolism in people with obesity. In 60 abdominally obese men, purified trans-10,cis-12 CLA raised insulin resistance by 19% and blood glucose by 4% and lowered HDL cholesterol, without fat loss beyond placebo [8]. In the same men it raised a lipid-peroxidation marker by 578% and C-reactive protein by 110% [9].

Some trials suggest CLA shifts body composition more than weight: in a 12-week trial in obese adults, 6.4 g a day raised lean mass by 0.64 kg [10], and after a crash diet CLA increased the regain of lean mass and resting metabolic rate but not weight maintenance [11]. Body-composition shifts like these don't translate into the weight loss that improves obesity-related disease.

Trials in people with obesity mostly used 3-3.4 g of CLA a day [8][12][17], often a 50:50 mix of the two main isomers [10][13]. Some went higher: 4.2 g a day in a 4-week trial [14] and 6-6.4 g a day in others [10][15]. Doses above 3.4 g a day were linked with slightly more weight loss (0.77 kg) in one meta-analysis, but that was a subgroup comparison [1], and the 6.4 g dose raised inflammatory markers [10].

Check whether a label gives the CLA content or the total oil; one crossover trial gave 8 g of oil a day [16]. The core treatment for obesity is a structured eating plan with at least 150 minutes a week of moderate activity, plus medicines or surgery when needed [4]; CLA, if used at all, is an add-on to that.

The review closest to this question pooled 13 placebo-controlled trials in overweight and obese adults: CLA lowered weight by 0.52 kg (95% CI -0.83 to -0.21), BMI by 0.23 kg/m2 and fat mass by 0.61 kg, raised lean mass by 0.19 kg, and did not change waist circumference [1]. Effects were larger in trials longer than 12 weeks (-1.29 kg) and in people over 44 [1].

A review limited to trials of at least 6 months in overweight and obese people found 0.70 kg more weight loss and 1.33 kg more fat loss, but four of its seven trials had serious reporting flaws, and the authors concluded CLA does not convincingly produce clinically relevant long-term effects [2]. Across 70 trials in adults generally, the fat-mass effect disappeared when only high-quality trials were analysed [5], and a 2021 review of weight-loss supplements put CLA at 1.08 kg, below its 2.5 kg threshold for clinical significance [3].

Some trials were positive. In 74 overweight or obese women, 3 g a day for 12 weeks reduced total and visceral fat and raised lean mass versus placebo [17]. In obese postmenopausal women with type 2 diabetes, CLA oil lowered BMI and total fat over 16 weeks [16]. In 25 abdominally obese men, 4 weeks of CLA slightly reduced sagittal abdominal diameter (a belly-fat measure) but nothing else [14].

Others found nothing. In 60 abdominally obese men, a 3.4 g CLA mixture did not change weight or body composition over 12 weeks [8]. In obese adults given 6 g a day through 28 placebo-controlled weeks of a low-calorie diet and refeeding, body composition did not differ from placebo; both groups then took CLA openly to 1 year [15]. In 40 adults with BMI over 27, CLA did not change BMI, total fat, or abdominal or liver fat on CT, and blood-vessel function worsened [18].

Keeping weight off is the hard part of obesity care, and CLA didn't help. Of 101 obese adults randomised after losing more than 8% of their weight, those who finished a year on 3.4 g a day regained 4.0 kg, the same as placebo [12]. After a very-low-calorie diet in overweight adults, CLA did not change the share of weight regained [11].

Added to exercise, CLA lowered body fat and insulin resistance slightly more than exercise alone, but did not reduce body weight [19]. In children aged 6-10 with overweight or obesity, about 7 months of CLA slowed the rise in BMI (0.5 vs 1.1) but lowered HDL cholesterol and bone mineral gain [13]. A trial in children with obesity found better insulin sensitivity with CLA than placebo (P=0.035) [20], which contrasts with the adult isomer data above.

Most people tolerate CLA. NIH's Office of Dietary Supplements reports few safety concerns at 2.4-6 g a day for up to 12 months, with abdominal discomfort, constipation, diarrhoea, loose stools and indigestion as the usual complaints, and possible adverse effects on blood lipids and glucose control [6]. Those metabolic effects matter most in obesity, where diabetes and heart risk are already raised: HDL cholesterol fell in several trials [8][10][13], some isomers may raise lipoprotein(a) [6], white cells rose in two trials [10][12], and the trans-10,cis-12 isomer worsened insulin resistance and raised C-reactive protein [8][9]. ODS also notes that CLA may lower breast-milk fat, so it is best avoided while breastfeeding [6]; none of the trials here tested it in pregnancy.

Rare case reports describe serious liver injury in women taking CLA weight-loss products, including acute hepatitis that cleared after stopping [21] and liver failure needing a transplant [22][23]. Cause isn't proven, partly because the products weren't tested for contaminants [6], and a 12-week trial in 74 women found no change in standard liver enzymes [17], but stop at once and seek care if you develop jaundice, dark urine or itching.

No formal drug-interaction studies of CLA were found. The practical conflicts follow from what trials showed: CLA can push glucose and insulin resistance up and HDL cholesterol down, and severe liver injury has been reported with CLA weight-loss products [6][8][22].